Targeting Toxoplasma parasites and their protein accomplices

Toxoplasmosis is an infectious disease caused by the parasite Toxoplasma gondii and is transmitted via contaminated food or feces. The infection can cause a range of symptoms that may be mild or severe, resulting in blindness and brain infection. Current T. gondii therapeutics are not very effective, so scientists need to further investigate potential drug targets.

Sheena Dass and a team of researchers from the Université Grenoble Alpes, France, identified seven genes responsible for expressing enzymes of metabolic interest in these parasites. Their recent article in the Journal of Lipid Research characterizes one of these enzymes, T. gondii acyl-CoA synthetase 3, or TgACS3.

TgACS3 was found to be localized in the cytosol of the parasite and to upregulate its parasitic growth while increasing its chances of survival within its host. Gas chromatography-mass spectrometry was implemented to analyze the lipid content in the parasite, which revealed the role of TgAC3 in the uptake and utilization of its host fatty acids, generating the parasite phospholipid layer, and maintaining the growth of new parasites.

This study is an important step towards achieving targeted therapeutic mechanisms in the treatment of Toxoplasmosis, as researchers can leverage the findings shared in a more rigorous analysis.